基质金属蛋白酶抑制剂和多西他赛协同抑制前列腺癌细胞存活的研究

The synergistic effect of matrix metalloproteinase inhibitor combine docetaxel on prostate cancer cell viability

目的观察基质金属蛋白酶抑制剂SB-3CT联合多西他赛对前列腺癌PC-3细胞存活率的影响。方法不同浓度的SB-3CT（5～20μmol／L）和多西他赛（0．1—1000．0nmol／L）分别或联合作用于细胞，采用水溶性四唑盐WST-1检测细胞存活率，药物联合指数法（CI）分析两种药物之间的相互作用。结果与单一用药比较，两药联合作用可以显著降低PC-3细胞存活率（P〈0．01），CI指数分析显示：在SB-3CT浓度为20μmol／L时，与多西他赛有轻中度的协同作用（0．5995〈CI〈0．9652）。结论SB-3CT联合多西他赛对PC-3的存活率有显著的抑制作用，且两药具有协同效应，可望成为一种潜在的治疗去势抵抗性前列腺癌的联合治疗方案。

Objective To investigate the effect of matrix metalloproteinase inhibitor SB - 3CT combine with docetaxel on proliferation of prostate cancer cell PC - 3. Methods The PC - 3 cells were treated with SB -3CT （5 -20 μ mol/L） or/and docetaxel （0. 1 -1 000.0 nmol/L）in different concentra- tions. The cell viability was detected with WST - 1 assay. Interactive effects of drugs were analyzed with combination index. Results Matrix metalloproteinase inhibitor SB -3CT combine with docetaxel could re- duce the viability of PC - 3 cells significantly compared with any single drug （ P 〈 0. 01 ）. When concentra- tion of SB - 3CT was 20 μmoL/L, mild to moderate synergistic effects were shown （ 0. 599 5 〈 CI 〈 0. 965 2）. Conclusion The viability of PC - 3 could be inhibited by combine therapy, and synergistic effects between two drugs were determined. It might be a potential therapy for castration resistant prostate